Copyright
©The Author(s) 2021.
Artif Intell Gastroenterol. Apr 28, 2021; 2(2): 42-55
Published online Apr 28, 2021. doi: 10.35712/aig.v2.i2.42
Published online Apr 28, 2021. doi: 10.35712/aig.v2.i2.42
Table 2 Artificial intelligence models that can help in predicting therapy responses
AI | Data adopted | Advantages | Control | Ref. |
ANN | Cox-identified risk factors | The ANN had the highest AUC (0.855) | Cox model, TNM 6th, BCLC and HPBA system (0.826, 0.639, 0.612, 0.711) | [35] |
CART model | Clinical and laboratorial parameters | The model successfully identified pre- and postoperative prognosis predictive factors | - | [36] |
Weka-based ANNs | Cox-identified risk factors (15 factors for DFS and 21 for OS) | The ANNs showed higher abilities of predicting DFS and OS | LR and decision tree model | [37,38] |
Radiomics-based DL CEUS model | Contrast-enhanced ultrasound | The model showed an AUC of 0.93 in predicting therapy response to TACE | Radiomics-based time-intensity curve of CEUS model (0.80) and radiomics-based B-Mode images model (0.81) | [40] |
Pretrained CNN "ResNet50" | Manually segmented CT images | The model showed AUCs for predicting CR, PR, SD and PD in training (0.97, 0.96, 0.95, 0.96) and validation (0.98, 0.96, 0.95, 0.94) cohorts | - | [41] |
Automatic predictive CNN model | Quantitative CT and BCLC stage | The model had a better prediction accuracy of 74.2% | ML model based on BCLC stage (62.9%) | [42] |
ANN | Clinical features | The models showed higher AUCs in predicting 1- and 2-yr DFS (0.94, 0.88) after RFA | Model built with 8 features for 1-yr DFS (0.80), and model built with 6 features for 2-yr DFS (0.76) | [45] |
- Citation: Yi PS, Hu CJ, Li CH, Yu F. Clinical value of artificial intelligence in hepatocellular carcinoma: Current status and prospect. Artif Intell Gastroenterol 2021; 2(2): 42-55
- URL: https://www.wjgnet.com/2644-3236/full/v2/i2/42.htm
- DOI: https://dx.doi.org/10.35712/aig.v2.i2.42